跳至主要内容
临床试验/ACTRN12607000316404
ACTRN12607000316404终止3 期

A prospective, multicentre, open, parallel group, randomised controlled trial to evaluate the effectiveness of passive versus active disclosure of genetic information to those at risk of familial cancer.

The Cancer Council Victoria0 个研究点目标入组 40 人开始时间: 2007年6月14日最近更新:

试验速览

阶段
3 期
状态
终止
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Educational / counselling / training
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 ot stated(—)
性别
All

入选标准

  • 1. A resident of Victoria
  • 2. Current client of a Victorian Familial Cancer Centre
  • 3. The first individual in the family to undertake mutation detection
  • 4. Positive pathogenic mutation detected for breast/ovarian or colorectal cancer
  • 5. Signed informed consent

排除标准

  • 1. Prior disclosure of genetic test results
  • 2. Other familal cancer syndromes eg, FAP (Familial Adenomatous Polyposis) or where predictive testing is used in childhood
  • 3. Individuals with pre-existing psychiatric illness or cognitive disorder that would preclude informed consent
  • 4. Individuals not fluent in written or spoken English language
  • 5. Individuals in whom the consent for testing was gained by proxy
  • 6. Another member of an affected family.

研究者

发起方
The Cancer Council Victoria

相似试验

进行中(未招募)
不适用
AN OPEN, MULTICENTRE, RANDOMISED, PARALLEL GROUP STUDY TO COMPARE IN MARGINAL OLD-FOR-OLD RENAL TRANSPLANT PATIENTS THE SAFETY AND EFFICACY OF TWO TREATMENTS:SEQUENTIAL MYCOPHENOLATE MOFETIL / DELAYED TACROLIMUS PLUS STEROIDS VS TACROLIMUS PLUS MYCOPHENOLATE MOFETILIN PATIENTS REQUIRING INDUCTION WITH ANTI-IL2 MONOCLONAL ANTIBODY
EUCTR2004-001205-99-ITFUJISAWA
进行中(未招募)
不适用
An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiFormTM pMDI compared with Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with mild to moderate-severe persistent, reversible asthma. - FLAIR studieAsthma bronchial.MedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchial
EUCTR2007-001634-13-BEMundipharma Research Ltd.200
进行中(未招募)
不适用
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.Asthma bronchialMedDRA version: 8.1Level: LLTClassification code 10003555Term: Asthma bronchial
EUCTR2006-005928-16-CZMundipharma Research Ltd.200
进行中(未招募)
不适用
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.Asthma bronchialMedDRA version: 8.1Level: LLTClassification code 10003555Term: Asthma bronchial
EUCTR2006-005928-16-HUMundipharma Research Ltd.200
进行中(未招募)
1 期
An open, randomised, parallel group, multicentre study to compare the efficacyand safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects withmild to moderate persistent, reversible asthma.
EUCTR2006-005928-16-FRMundipharma Research Ltd.